Pressure-sensitive lens tolerable and safe for 24 hours


A new pressure-sensitive contact lens is tolerable and safe over a 24-hour wearing period for healthy subjects and glaucoma sufferers.

A new pressure-sensitive contact lens is tolerable and safe over a 24-hour wearing period for healthy subjects and glaucoma sufferers, according to a paper in the Journal of Glaucoma.

Dr Katrin Lorenz et al., Department of Ophthalmology, University Medical Centre, Johannes Gutenberg-University Mainz, Germany, included 20 healthy subjects and 20 age-matched glaucoma patients in a prospective, single-centre, open, observational parallel group study.

The study incorporated the Sensimed Triggerfish Sensor, a soft disposable contact lens embedded with a telemetry chip and strain gauge sensor for continuous IOP monitoring. The sensor was implanted in one eye of each patient for 24 hours. A visual analogue scale was used to evaluate tolerability. The safety parameters included best-corrected visual acuity, pachymetry, epithelial defects, conjunctival erythema and corneal topography.

The 24-hour wearing period was completed by 19 healthy participants and 19 glaucoma patients. Pain or inappropriate fitting of the sensor contributed towards early discontinuation. Mean tolerability was 21.8 in the healthy group and 26.8 in the glaucoma group.

Corneal epithelial staining increased from 0.4 and 1.0 at baseline to 1.8 and 2.8 in the healthy and glaucoma groups, respectively. There were no statistically differences between the two groups, meaning they both had a similar safety and tolerability profiles.

To read the abstract please click here.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.